Home>>Signaling Pathways>> Metabolism>> Carbohydrate Metabolism>>Sodium Oxamate

Sodium Oxamate (Synonyms: Oxalic Acid monoamide, Oxamic Acid)

Catalog No.GC44911

Sodium oxamate as PDK1 and LDHA inhibitor with IC50 values (μg/mL) of 15.60.

Products are for research use only. Not for human use. We do not sell to patients.

Sodium Oxamate Chemical Structure

Cas No.: 565-73-1

Size Price Stock Qty
100mg
$15.00
In stock
500mg
$17.00
In stock
1g
$20.00
In stock
5g
$25.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Protocol Chemical Properties Product Documents Related Products

Sodium oxamate as PDK1 and LDHA inhibitor with IC50 values (μg/mL) of 15.60[1]. Sodium oxamate can specifically inhibit LDH-A. Sodium oxamate by down-regulating CDK1/cyclin B1 Pathway induces G2/M cell cycle arrest and promotes apoptotic targets by increasing ROS production in mitochondria[4,5].

Sodium oxamate enhances the suppressive effects of PARP inhibitors on ovarian cancer without BRCA mutations, remarkably promoting the inhibitory effects of PARP inhibitors on wild-type BRCA ovarian cancer cells[3]. In the human PC cell line, Sodium oxamate caused cell inhibition, resulting in increased sensitivity of CRPC cells to DOC, and the combination of DOC and Sodium oxamate promoted apoptosis compared with DOC or Sodium oxamate alone[2].

Sodium oxamate reduces the growth of colorectal cancer in CRC mice, by restoring the down-regulated MMR functional proteins and attenuating chemotherapy resistance to oxaliplatin caused by C. tropicalis[6]. NETosis and lactate accumulation during LPS induced sepsis in mice was inhibited by sodium oxamate [7].

References:
[1]: Kamal S, Derbala HA, et,al. Synthesis, Biological, and Molecular Docking Studies on 4,5,6,7-Tetrahydrobenzo[b]thiophene Derivatives and Their Nanoparticles Targeting Colorectal Cancer. ACS Omega. 2021 Oct 25;6(43):28992-29008. doi: 10.1021/acsomega.1c04063. PMID: 34746589; PMCID: PMC8567357.
[2]: Muramatsu H, Sumitomo M, et,al. Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells. Oncol Rep. 2019 Jul;42(1):224-230. doi: 10.3892/or.2019.7171. Epub 2019 May 24. PMID: 31180564.
[3]: Xiang J, Zhou L, et,al. LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells. Aging (Albany NY). 2021 Dec 16;13(24):25920-25930. doi: 10.18632/aging.203780. Epub 2021 Dec 16. PMID: 34919531; PMCID: PMC8751605.
[4]: Thornburg JM, Nelson KK, et,al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 2008;10(5):R84. doi: 10.1186/bcr2154. Epub 2008 Oct 15. PMID: 18922152; PMCID: PMC2614520.
[5]: Zhai X, Yang Y, et,al. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep. 2013 Dec;30(6):2983-91. doi: 10.3892/or.2013.2735. Epub 2013 Sep 19. PMID: 24064966.
[6]: Qu J, Sun Z, et,al. tropicalis promotes chemotherapy resistance in colon cancer through increasing lactate production to regulate the mismatch repair system. Int J Biol Sci. 2021 Jul 2;17(11):2756-2769. doi: 10.7150/ijbs.59262. PMID: 34345205; PMCID: PMC8326116.
[7]: Awasthi D, Nagarkoti S, et,al. Glycolysis dependent lactate formation in neutrophils: A metabolic link between NOX-dependent and independent NETosis. Biochim Biophys Acta Mol Basis Dis. 2019 Dec 1;1865(12):165542. doi: 10.1016/j.bbadis.2019.165542. Epub 2019 Aug 29. PMID: 31473341.

Reviews

Review for Sodium Oxamate

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sodium Oxamate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.